Treasury stock

Notice Regarding the Completion of Payment for Disposal of Treasury Stock for Restricted Stock Remuneration

Retrieved on: 
Wednesday, June 14, 2023

TOKYO, June 14, 2023 (GLOBE NEWSWIRE) -- Internet Initiative Japan Inc. (“IIJ”, the “Company”, TSE Prime Market: 3774) announced that the payment regarding the disposal of treasury stock as the restricted stock remuneration, resolved at the IIJ’s Board of Directors held on May 18, 2023, has been completed as described in the following table.

Key Points: 
  • TOKYO, June 14, 2023 (GLOBE NEWSWIRE) -- Internet Initiative Japan Inc. (“IIJ”, the “Company”, TSE Prime Market: 3774) announced that the payment regarding the disposal of treasury stock as the restricted stock remuneration, resolved at the IIJ’s Board of Directors held on May 18, 2023, has been completed as described in the following table.
  • For details, please refer to the “Notice Regarding the Disposal of Treasury Stock for Restricted Stock Remuneration” disclosed on May 18, 2023.

Partial Disposal of Shares of Common Stock Held by Nippon Telegraph and Telephone Corporation (Largest Shareholder), Acquisition of Shares of Common Stock by KDDI Corporation, Acquisition of Treasury Stock, etc.

Retrieved on: 
Thursday, May 18, 2023

TOKYO, May 18, 2023 (GLOBE NEWSWIRE) -- Internet Initiative Japan Inc. (“IIJ”, the “Company”, TSE Prime: 3774) hereby announces that a series of capital transactions are scheduled to be implemented for a portion of IIJ’s shares of common stock held by Nippon Telegraph and Telephone Corporation (“NTT”), which is the largest shareholder of IIJ, in accordance with the NTT’s policy of disposing of the shares held by it. IIJ also hereby announces changes in Other Affiliated Company and Major Shareholders (each, as defined in the Financial Instruments and Exchange Act or relevant Cabinet Office Order) of IIJ as well as certain other matters.

Key Points: 
  • As of today, NTT has entered into the share purchase agreement with KDDI Corporation (“KDDI”) to transfer 18,707,000 shares (shareholding percentage (Note): 10.00%) out of the shares of IIJ’s common stock held by NTT to KDDI through off-market transaction (the “Share Transfer”).
  • The Share Transfer falls under a secondary offering of IIJ’s common stock.
  • NTT has informed IIJ that NTT intends to tender 3,928,500 shares (shareholding percentage (Note): 2.10%) out of the shares of IIJ’s common stock held by NTT in the Acquisition of Treasury Stock.
  • NTT has informed IIJ that NTT intends to continue holding such shares for the time being.

Notice Regarding the Disposal of Treasury Stock for Restricted Stock Remuneration

Retrieved on: 
Thursday, May 18, 2023

The Disposal of Treasury Stock is conditioned on the Securities Registration Statement taking effect in accordance with the Financial Instruments and Exchange Act.

Key Points: 
  • The Disposal of Treasury Stock is conditioned on the Securities Registration Statement taking effect in accordance with the Financial Instruments and Exchange Act.
  • (The Company conducted a stock split at a ratio of two-for-one with a record date of December 31, 2020.
  • of IIJ-Global, taking into consideration our consolidated financial results, and non-consolidated financial results of IIJ and IIJ-Global, along with the disposal of treasury stock as the restricted stock remuneration for Eligible Directors, etc.
  • Moreover, issuance or disposal of the Allotted Shares shall be conditional upon a restricted stock allocation agreement (the “Allotment Agreement”) concluded between the Company and each Eligible Directors, etc.

Notice Regarding the Disposal of Treasury Stock for Restricted Stock Remuneration

Retrieved on: 
Thursday, May 26, 2022

The Disposal of Treasury Stock is conditioned on the Securities Registration Statement taking effect in accordance with the Financial Instruments and Exchange Act.

Key Points: 
  • The Disposal of Treasury Stock is conditioned on the Securities Registration Statement taking effect in accordance with the Financial Instruments and Exchange Act.
  • (The Company conducted a stock split at a ratio of two-for-one with a record date of December 31, 2020.
  • of IIJ-Global, taking into consideration our consolidated financial results, and non-consolidated financial results of IIJ and IIJ-Global, along with the disposal of treasury stock as the restricted stock remuneration for Eligible Directors, etc.
  • Moreover, issuance or disposal of the Allotted Shares shall be conditional upon a restricted stock allocation agreement (the Allotment Agreement) concluded between the Company and each Eligible Directors, etc.

Travis Perkins: Total Voting Rights

Retrieved on: 
Tuesday, August 3, 2021

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • In conformity with DTR5.6.1R, the Company notifies the market of the following:
    As at the date of this announcement, the Company's issued share capital consists of 225,025,926 ordinary shares with a nominal value of 11.205105 pence each ("Ordinary Shares"), with attached voting rights.
  • The Company does not hold any Ordinary Shares in Treasury.
  • Therefore, the total number of Ordinary Shares with attached voting rights is 225,025,926.

DGAP-News: BP p.l.c.: Total Voting Rights

Retrieved on: 
Tuesday, August 3, 2021

As at 30 July 2021, the issued share capital of BP p.l.c.

Key Points: 
  • As at 30 July 2021, the issued share capital of BP p.l.c.
  • The number of ordinary shares which have been bought back and are held in treasury by BP p.l.c.
  • These treasury shares are not taken into consideration in relation to the payment of dividends and voting at shareholder meetings.
  • The total number of voting rights in BP p.l.c.

Aperam announces a share buyback program

Retrieved on: 
Friday, July 30, 2021

Simultaneously, the Mittal family has declared its intention to enter into a share repurchase agreement with Aperam, to sell each trading day on which Aperam has purchased shares under the Program, an equivalent number of shares, at the proportion of the Mittal family's stake of 40.96% of issued and outstanding shares of Aperam, at the same price as the shares repurchased on the open market.

Key Points: 
  • Simultaneously, the Mittal family has declared its intention to enter into a share repurchase agreement with Aperam, to sell each trading day on which Aperam has purchased shares under the Program, an equivalent number of shares, at the proportion of the Mittal family's stake of 40.96% of issued and outstanding shares of Aperam, at the same price as the shares repurchased on the open market.
  • The effect of the share repurchase agreement is to maintain Mittal family's voting rights in Aperam's issued share capital (net of Treasury Shares) at the current level, pursuant to the Program.
  • The shares acquired under this buyback program are intended:
    to be cancelled to reduce the share capital of Aperam, and
    to meet Aperam's obligations arising from employee share programs.
  • Aperam is a global player in stainless, electrical and specialty steel, with customers in over 40 countries.

Millicom to repurchase own shares

Retrieved on: 
Thursday, July 29, 2021

Luxembourg, July 29, 2021 On May 4, 2021, the Annual General Meeting of Shareholders (AGM) of Millicom resolved to authorize (the Authorization) the Board of Directors of Millicom (the Board) to adopt a share repurchase plan.

Key Points: 
  • Luxembourg, July 29, 2021 On May 4, 2021, the Annual General Meeting of Shareholders (AGM) of Millicom resolved to authorize (the Authorization) the Board of Directors of Millicom (the Board) to adopt a share repurchase plan.
  • Based on the Authorization, the Board has decided to initiate a repurchase program comprising not more than 5,000,000 Swedish Depository Receipts representing the Companys ordinary shares (SDRs).
  • The repurchase program will be managed by an investment firm which makes its trading decisions concerning the timing of the purchases of SDRs independently of Millicom.
  • As of the date of this press release, the total number of outstanding shares in Millicom is 101,739,217 of which 178,555 are held by Millicom as treasury shares.

Joy Spreader Intends to Conduct Share Buy Back of 10% Shares at Maximum

Retrieved on: 
Friday, July 30, 2021

The Board believes that the shares of the Company have been trading in the open market at a price which does not fully reflect the underlying value of the Company.

Key Points: 
  • The Board believes that the shares of the Company have been trading in the open market at a price which does not fully reflect the underlying value of the Company.
  • The Proposed Share Buy Back and subsequent cancellation of the bought back shares could enhance the value of the shares, thereby improving the return to shareholders of the Company.
  • In addition, the Company is in a stable financial position and is able to maintain sufficient financial resources to meet the needs of its continuous business growth while carrying out the buy back of shares.
  • Analysts suggest that the Proposed Share Buy Back by Joy Spreader demonstrates the Board's recognition of and confidence in its long-term value, which will also be in the interest of the Company and its shareholders as a whole.

Zealand Pharma A/S – Final Transactions Under Share Repurchase Program

Retrieved on: 
Tuesday, July 27, 2021

The details for each transaction made under the share repurchase program are included as an appendix to this announcement.

Key Points: 
  • The details for each transaction made under the share repurchase program are included as an appendix to this announcement.
  • With the transactions stated above, Zealand owns a total of 218,410 shares with a nominal value of DKK 1 each as treasury shares, corresponding to 0.5% of the total share capital.
  • The total share capital of the company is DKK 43,541,838 with a nominal value of DKK 1 each.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines.